Evidence map›Paper›PMID 41250208›Full record

ArticleAlzheimer's research & therapy2025

An accessible and efficient mobile eye-tracking application for community-based cognitive impairment screening in China.

Mingxia Wei, Jincheng Li, Tongyao You, Yu Yu, Jiaying Lu, Suzhen Liang, Zishuo Jin, Qi Han, Chuantao Zuo, Jianfeng Ye and 7 more

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mingxia Wei *Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Jincheng Li *State Key Laboratory of Genetics and Development of Complex Phenotypes, Human Phenome Institute, Research and Innovation Center, Shanghai Pudong Hospital, Zhangjiang Fudan International Innovation Center, and National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Tongyao YouDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Yu YuDepartment of R&D, NeuroWeave, Co., Ltd, Shanghai, China.
Jiaying LuDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Suzhen LiangDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Zishuo JinDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Qi HanDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Chuantao ZuoDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Jianfeng YeDepartment of R&D, NeuroWeave, Co., Ltd, Shanghai, China.
Jintai YuDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Xingdong ChenState Key Laboratory of Genetics and Development of Complex Phenotypes, Human Phenome Institute, Research and Innovation Center, Shanghai Pudong Hospital, Zhangjiang Fudan International Innovation Center, and National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Qiang DongDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Wenwen WuShanghai Xuhui Hongmei Community Health Center, Shanghai, China.
Yingzhe WangDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China. yingzhewang@fudan.edu.cn.
Yanfeng JiangState Key Laboratory of Genetics and Development of Complex Phenotypes, Human Phenome Institute, Research and Innovation Center, Shanghai Pudong Hospital, Zhangjiang Fudan International Innovation Center, and National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China. yanfengjiang@fudan.edu.cn.
Mei CuiDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China. cuimei@fudan.edu.cn.

Funding

Ministry of Science and Technology of the People's Republic of China STI2030-Major Projects 2030 2021ZD0201806National Key Research and Development Program of China 2023YFC3606300National Natural Science Foundation of China 82271221National Natural Science Foundation of China 82373658Natural Science Foundation of Shanghai Municipality 22ZR1405300Shanghai Municipal Health Commission 20234Z0013Shanghai Municipal Health Commission Clinical Research Special Program for the Health Industry 20244Y0103
6 · The paper itself

Abstract

backgroundCognitive impairment (CI) poses a major global health challenge. In China, neuropsychological scales, regarded as the gold standard for cognitive diagnosis, are largely inaccessible in resource-limited communities. The Mobile Eye-Tracking Application (m-ETA), which captures and quantifies eye movement features, has emerged as a promising tool for CI screening.

methodsWe developed a tablet-based m-ETA using a two-step approach. First, a logistic regression (LR) model was trained to discriminate dementia based on six oculometric features in a hospital cohort (N = 204), and regression analyses were conducted to validate the biological relevance of these features with Alzheimer's Disease-related phenotypes in an exploratory dataset (N = 101). Second, the generalizability and accuracy of the LR model were externally validated in a community-based cohort (N = 433) and further evaluated in two real-world community populations (N = 2,685). Model performance was assessed using sensitivity, specificity, negative predictive value (NPV), and area under the ROC curve (AUC).

resultsm-ETA achieved high diagnostic accuracy for dementia (AUC = 0.99). Regression analyses confirmed that the m-ETA-derived oculometric features were significantly associated with cognitive performance, brain atrophy, and tau deposition in the exploratory dataset (all P < 0.05). m-ETA accurately detected CI (AUC = 0.80), with excellent negative predictive value for ruling out CI, and identified individuals with lower cognition performance across diverse communities.

conclusionsm-ETA offers a low-cost, non-invasive, and efficient tool for large-scale CI screening, particularly suited to underserved and low-literacy communities in China.

Indexed as

Cognitive DysfunctionEye-Tracking TechnologyMobile ApplicationsAgedAged, 80 and overChinaCohort StudiesFemaleHumansMaleMass ScreeningMiddle AgedNeuropsychological Tests

Identifiers

PMID41250208
PMCPMC12625592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.